바이러스 불활성화 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Viral Inactivation Market Size, Share & Trends Analysis Report By Product & Service (Kits & Reagents), By Application (Vaccines & Therapeutics), By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,206,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,585,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,343,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

바이러스 불활성화 시장 성장 및 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 바이러스 불활성화 시장 규모는 2025-2030년 동안 11.58%의 연평균 복합 성장률(CAGR)을 보이고, 2030년까지 13억 7,160만 달러에 달할 것으로 예상됩니다.

제약-바이오 기업 수 증가, FDA의 의약품 승인 증가, 생명과학 산업의 성장, 신규 치료제 및 의약품 개발에 대한 정부 자금 지원 증가 등이 주요 성장 요인으로 꼽힙니다.

제약 및 바이오 제약 산업은 기업 수의 꾸준한 증가, 신약 출시, 신약 발견으로 큰 성장을 달성하고 있습니다. 전 세계에서 질병이 증가함에 따라 신약 및 치료법 개선에 대한 요구가 전 세계에서 증가하고 있습니다. 질병 치료를 위한 새로운 치료법을 찾아야 할 필요성과 함께 주요 기업의 연구개발에 대한 투자 증가는 제약 및 바이오 제약 기업의 거대한 성장에 기여하고 성장을 가속화하고 있습니다.

신약은 건강상의 이점을 높이기 위해 기업에 의해 개발되고 있습니다. FDA에 따르면 2014년에는 41개의 신약이 승인되었고, 다음 해에는 45개의 신약이 승인되었으며, 이 또한 성장에 기여하고 있습니다. 이 또한 성장에 기여하고 있습니다.

최근 수년간 제약 및 생명공학 산업에 막대한 자금이 투입되고 있습니다. 민간 기업이 신약과 치료법 개발에 크게 기여하고 있지만, 새로운 치료법 연구개발에 대한 정부 지출도 증가하고 있습니다. 자금 지원 증가는 최근 수년간 FDA 승인 건수 증가로 이어졌습니다. 이러한 모든 요인들이 바이러스 불활성화 시장의 거대한 성장에 기여하고 있습니다.

바이러스 비활성화 시장 보고서 하이라이트

• 키트 및 시약 제품 부문은 2024년 57.37%의 최대 매출 점유율로 시장을 주도했습니다.
• 용도별로는 백신 및 치료 부문이 2024년 34.41%로 가장 큰 매출 점유율을 차지하며, 이는 유전자 치료 및 줄기세포 연구와 같은 연구개발 분야에 대한 투자 증가에 기인합니다.
• 2024년에는 제약 및 생명공학 기업 부문이 38.51%의 가장 큰 매출 점유율로 시장을 독점했습니다.
• 북미가 가장 큰 점유율을 차지한 이유는 만성질환 발생을 억제하기 위한 의료 개혁과 함께 유력한 기업이 존재하고, 정교한 인프라를 이용할 수 있기 때문입니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 바이러스 불활성화 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 산업 분석 툴
  • Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 바이러스 불활성화 시장 : 제품·서비스별, 추정·동향 분석

• 제품·서비스 부문 대시보드
• 세계의 바이러스 불활성화 시장의 제품·서비스 변동 분석
• 세계의 바이러스 불활성화 시장 규모와 동향 분석, 제품·서비스별, 2018-2030년
• 키트·시약
• 시스템과 부속품
• 서비스

제5장 바이러스 불활성화 시장 : 용도별, 추정·동향 분석

• 용도 부문 대시보드
• 세계의 바이러스 불활성화 시장의 용도 변동 분석
• 세계의 바이러스 불활성화 시장 규모와 동향 분석, 용도별, 2018-2030년
• 백신·치료
• 줄기세포 제품
• 혈액과 혈액 제품
• 조직/조직 제품
• 세포와 유전자 치료

제6장 바이러스 불활성화 시장 : 최종 용도별, 추정·동향 분석

• 최종 용도 부문 대시보드
• 세계의 바이러스 불활성화 시장의 최종 용도 변동 분석
• 세계의 바이러스 불활성화 시장 규모와 동향 분석, 최종 용도별, 2018-2030년
• 제약·바이오테크놀러지 기업
• CRO
• 학술연구기관
• 기타

제7장 바이러스 불활성화 시장 : 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모와 예측과 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 참여 기업
• 기업 시장 현황 분석, 2024년
• 참여 기업 개요
  • Charles River Laboratories, Inc.
  • Clean Cells
  • Cytiva(Danaher Corporation)
  • Merck KGaA
  • Mettler Toledo
  • Parker Hannifin Corp
  • Rad Source Technologies Inc
  • Sartorius AG
  • Texcell SA
  • Vironova AB

KSA

영문 목차

영문목차

Viral Inactivation Market Growth & Trends:

The global viral inactivation market size is estimated to reach USD 1,371.6 million by 2030, registering a CAGR of 11.58% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rise in the number of pharmaceutical and biopharmaceutical companies, increase in FDA drug approvals, growth of the life sciences industry, increase in government funding for novel therapies, and drug development are some of the major factors contributing to the growth.

Immense growth has been witnessed in the pharmaceutical and biopharmaceutical industry with a steady rise in the number of companies, drug launches, and new drug discoveries. With an increase in the number of diseases worldwide, the need for new & improved drugs and therapies has been witnessed on a global front. Increase in investment by top players in research and development coupled with the need to find new therapies for the treatment of diseases has contributed to immense growth of pharmaceutical and biopharmaceutical companies, thereby accelerating growth.

Newer drugs are being developed by companies to offer incremental health benefits. Changing lifestyle of people across the globe and adoption of sedentary living habits are primary reasons responsible for the increase in the number of chronic diseases that require drugs and therapies for treatment. According to the FDA, in the year 2014, 41 novel drugs were approved and 45 in the consequent year. This has also been contributing to growth.

Immense funding has been witnessed in the pharmaceutical and biotechnology industries in the recent years. It has been observed that private players are the major contributors for the development of new drugs and therapies, however, there has been increasing government spending on the research and development of new therapies. Increase in funding has also resulted in growth in number of FDA approvals over the recent years. All these factors have been contributing to the immense growth of the viral inactivation market.

Viral Inactivation Market Report Highlights:

• The kits & reagents product segment led the market with the largest revenue share of 57.37% in 2024, attributed to the rise in biopharmaceutical and biotechnological companies worldwide.
• By application, the vaccines and therapeutics segment held the largest revenue share of 34.41% in 2024, attributed to the rising investments in R&D applications such as gene therapy and stem cell research.
• In 2024, the pharmaceutical and biotechnology companies segment led the market with the largest revenue share of 38.51%, attributed to the growth of pharmaceutical and biopharmaceutical companies.
• North America accounted for the largest share owing to presence of dominant players and availability of sophisticated infrastructure along with healthcare reforms to curb the incidence of chronic diseases.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Viral Inactivation Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Demand for Biopharmaceuticals
    • 3.2.1.2. Technological Advancements in Viral Inactivation
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost of Viral Inactivation Techniques
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Viral Inactivation Market: Product & Services Estimates & Trend Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. Global Viral Inactivation Market Product & Service Movement Analysis
• 4.3. Global Viral Inactivation Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
• 4.4. Kits & Reagents
  • 4.4.1. Kits & Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Systems & Accessories
  • 4.5.1. Systems & Accessories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Viral Inactivation Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Viral Inactivation Market Application Movement Analysis
• 5.3. Global Viral Inactivation Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Vaccines & Therapeutics
  • 5.4.1. Vaccines & Therapeutics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Stem Cell Products
  • 5.5.1. Stem Cell Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Blood & Blood Products
  • 5.6.1. Blood & Blood Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Tissue/ Tissue Products
  • 5.7.1. Tissue/ Tissue Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Cellular and Gene Therapy
  • 5.8.1. Cellular and Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Viral Inactivation Market: End Use Estimates & Trend Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Global Viral Inactivation Market End Use Movement Analysis
• 6.3. Global Viral Inactivation Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnological Companies
  • 6.4.1. Pharmaceutical & Biotechnological Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. CROs
  • 6.5.1. CROs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Academic and Research Institutes
  • 6.6.1. Academic and Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Viral Inactivation Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.4. North America
  • 7.4.1. North America Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Mexico Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. UK Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Germany Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Spain Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Denmark Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Sweden Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Norway Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Japan Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. India Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Australia Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Thailand Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. South Korea
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. South Korea Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Brazil Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. South Africa Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Saudi Arabia Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. UAE Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Kuwait Viral Inactivation Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Participant's Overview
  • 8.3.1. Charles River Laboratories, Inc.
    • 8.3.1.1. Participant's Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Product/Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Clean Cells
    • 8.3.2.1. Participant's Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Product/Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Cytiva (Danaher Corporation)
    • 8.3.3.1. Participant's Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Product/Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Merck KGaA
    • 8.3.4.1. Participant's Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Product/Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Mettler Toledo
    • 8.3.5.1. Participant's Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Product/Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Parker Hannifin Corp
    • 8.3.6.1. Participant's Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Product/Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Rad Source Technologies Inc
    • 8.3.7.1. Participant's Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Product/Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Sartorius AG
    • 8.3.8.1. Participant's Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Product/Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Texcell SA
    • 8.3.9.1. Participant's Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Product/Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Vironova AB
    • 8.3.10.1. Participant's Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Product/Service Benchmarking
    • 8.3.10.4. Strategic Initiatives

관련자료